Introduction
============

Infant acute lymphoblastic leukemia (ALL) refers to ALL arising in infants prior to 12 months of age. Infant ALL is less common but more aggressive than pediatric ALL, generally with a poorer outcome ([@ref-7]; [@ref-42]). Despite advances in the treatment of pediatric ALL, \>50% of patients with infant ALL relapse within five years of diagnosis, and the four-year event-free survival is \<50% ([@ref-23]; [@ref-40]). Approximately 80% of infant ALL cases are characterized genetically by rearrangements in the mixed lineage leukemia gene (*MLL*, also known as *KMT2A*, located on chromosome 11q23) ([@ref-30]). These rearrangements occur in nearly 100% of infants with congenital leukemia and approximately 5% of pediatric ALL patients, with predicted inferior outcomes ([@ref-54]). Previous studies have shown that infant ALL with *MLL* rearrangements (*MLL*-R) were clinically distinct, and were characterized by high white blood cell counts, hepatosplenomegaly, and central nervous system and skin involvement ([@ref-23]). The 4-5-year event-free survival for *MLL*-R infant ALL patients was 29.1%--43.2%, compared with 56.9%--95.5% for patients without *MLL* rearrangements (non-*MLL*-R) ([@ref-21]). Standard strategy for *MLL*-R infant ALL is intensive chemotherapy with or without hematopoietic stem cell transplantation (HSCT). Although allogeneic HSCT may contribute to improve the inferior prognosis of *MLL*-R infant ALL, it was restricted to some patients because of early relapse before HSCT ([@ref-51]). Early (within 4 months of the first induction course) use of allogeneic HSCT could help to reduce the rate of early relapse, however, could not ovecome the high risk factors including younger than 90 days at diagnosis, central nervous system involvment and poor prednisone response ([@ref-29]). Recent studies evaluated the effect of several innovative approaches such as *FLT3* inhibitors, epigenetic agents and immunotherapy in *MLL*-R infant ALL, the results were still far from satisfactory ([@ref-7]). Thus novel treatment targets and molecular-targeted strategies are required to improve outcomes of infant ALL patients with *MLL*-R.

More than 90 different *MLL* partner genes have been identified to date. Frequent *MLL* rearrangements in infant ALL include fusions with *AF4* (49%), *ENL* (22%), *AF9* (16%), and *AF10* (6%) ([@ref-35]). All types of rearrangements in *MLL* were independently associated with an unfavorable prognosis ([@ref-42]). Several studies found that *MLL* rearrangements occurred in utero, resulting in rapid progression to leukemia ([@ref-7]; [@ref-16]; [@ref-17]). Notably, this phenomenon showed a high concordance rate between identical twins ([@ref-19]; [@ref-21]). These findings revealed that *MLL* rearrangements may initiate leukemogenesis for *MLL*-R infant ALL. However, *MLL-AF4* expression alone was not sufficient to induce leukemia in human embryonic stem cell-derived hematopoietic cells, and additional genetic candidates were required ([@ref-49]). These results suggested that the mechanisms responsible for *MLL*-R infant ALL are distinct from those acting during leukemogenesis in childhood and non-*MLL*-R infant ALL.

We investigated the molecular mechanisms of *MLL*-R infant ALL by determining differentially expressed genes (DEGs) between *MLL*-R and non-*MLL*-R infant ALL, using available microarray datasets, followed by bio-functional enrichment of identified DEGs. These results will provide new insights into the molecular mechanisms behind ALL in infants with *MLL* rearrangements, and help to identify new diagnostic bio-markers and candidate therapeutic targets.

Materials & Methods
===================

Microarray data collection
--------------------------

Microarray expression data in the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo>) ([@ref-4]), ArrayExpress database (<https://www.ebi.ac.uk/arrayexpress/>) and The Cancer Genome Atlas (TCGA) database (<https://cancergenome.nih.gov/>), were searched using the keywords "acute lymphoblastic leukemia", and data containing expression profiles of *MLL*-R compared with non-*MLL*-R infant ALL cases were selected manually. Raw CEL files were downloaded for further analysis.

Identification of DEGs
----------------------

Gene expression profile data were preprocessed using the robust multi-array average (RMA) algorithm by Affy package in R (version 1.58.0) ([@ref-18]), including background adjustment, normalization, and summarization. According to annotation files, the mean value was computed for several probes matched to a specific gene, and used as the expression value of that gene. DEGs between *MLL*-R and non-*MLL*-R infant ALL cases were identified using the Bayesian method by Limma package in R (version 3.36.5) ([@ref-43]). ---log2 fold change (FC)---\>1 (log2FC \>1 defined as upregulated genes, log2FC \<−1 defined as downregulated genes) and a *P* value \<0.01 were considered as threshold points.

Gene functional enrichment analysis
-----------------------------------

Gene ontology (GO) functional annotation analyses including biological processes (BP), cellular components (CC), molecular function (MF) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 ([@ref-26]), with a default cut-off criterion of count ≥2 and *P* value \<0.1.

Protein-protein interaction network construction and analysis
-------------------------------------------------------------

A protein-protein interaction (PPI) network of DEGs was constructed using the STRING (version 10.5, <http://www.string-db.org/>) database ([@ref-56]), with minimum required interaction score \>0.4 (median confidence). The PPI network was visualized using Cytoscape (version 3.7.1, <http://www.cytoscape.org/>) ([@ref-47]). Bio-functional modules in the PPI network were explored using a plug-in MCODE (version 1.4.2, <http://apps.cytoscape.org/apps/MCODE>) in Cytoscape with Node Score Cutoff of 0.2 and K-Core of 2. Hub genes were screened using the plug-in CytoHubba (version 2.1.6, <http://apps.cytoscape.org/apps/cytohubba>) in Cytoscape with methods including maximal clique centrality, degree, and betweenness.

Drug-gene interactions analyses
-------------------------------

Drug-gene interactions were searched from the Drug-Gene Interaction database (DGIdb, v3.0.2, <http://www.dgidb.org/>) ([@ref-14]), which mines known or predicted interactions from existing databases and literature, using the list of hub genes. The preset filter was setted to antineoplastic which was defined by the inclusion of anti-neoplastic drug-gene interaction source databases (e.g., My Cancer Genome, PharmGKB, DrugBank), while advanced filters were setted to 20 source databases, 41 gene categories and 51 interaction types. The interactions were visualized using Cytoscape.

Results
=======

Microarray datasets and patient characteristics
-----------------------------------------------

Based on searches in the GEO, ArrayExpress and TCGA databases, two microarray datasets, [GSE68720](GSE68720) and [GSE19475](GSE19475), that met the criteria mentioned in methods section, were selected for analysis. Both datasets were generated using the [GPL570](GPL570) Affymetrix Human Genome U133 Plus 2.0 Array platform. There were 80 *MLL*-R and 17 non-*MLL*-R infant ALL samples in the [GSE68720](GSE68720) dataset, and 59 and 14, respectively, in the [GSE19475](GSE19475) dataset. The age range of the 139 *MLL*-R infant ALL cases (65 male, 73 female and one unknown) was 0--363 days, and the age range of the 31 non-*MLL*-R infant ALL cases (22 male, nine female) was 0--365 days. *MLL*-R infant ALL displayed 77 (55.4%) *AF4*, 38 (27.3%) *ENL*, 14 (10.1%) *AF9*, and 10 (7.2%) other gene fusions.

Identification of DEGs
----------------------

To probe significant alterations of gene expression profile related to *MLL*-R, differential expression analysis of genes was performed using Limma package. Based on the cut-off criteria, a total of 320 DEGs, including 236 up-regulated and 84 down-regulated genes, were identified between *MLL*-R and non-*MLL*-R infant ALL samples. The top five up-regulated DEGs were *LAMP5*, *PROM1*, *CCNA1*, *MEIS1*, and *KCNK12*, and the top five down-regulated DEGs were *MME*, *CMTM8*, *ELK3*, *NRN1*, and *PLEKHG4B* ([Fig. 1](#fig-1){ref-type="fig"}).

![Heat map of the top 20 up-regulated and down-regulated DEGs.\
DEGs were identified between *MLL*-R (*n* = 139) and non-*MLL*-R (*n* = 31) infant ALL samples by the cutoff \| log2 fold change (FC) \| \> 1 and *P* value \<0.01. Each row represents a single gene, each column represents a sample. The gradual color change from green to magenta represents the gene expression values change from low to high. DEG, differentially expressed genes; *MLL*-R, Mixed Lineage Leukemia rearrangement.](peerj-07-7628-g001){#fig-1}

GO functional annotation and KEGG pathway analyses
--------------------------------------------------

To identify the biologic functions of DEGs, GO functional annotation and KEGG pathway analyses were carried out. The results showed that up-regulated DEGs were enriched in 62 BP, 21 CC, and 22 MF terms, and down-regulated DEGs were enriched in 34 BP, 22 CC, and 17 MF terms. The top five significant terms are shown in [Figs. 2](#fig-2){ref-type="fig"}, [3](#fig-3){ref-type="fig"} and [4](#fig-4){ref-type="fig"}. The up-regulated DEGs were also enriched in seven KEGG pathways, mainly involving transcriptional regulation and signaling pathways, and down-regulated DEGs were enriched in three KEGG pathways including Alzheimer's disease, TGF-beta signaling pathway, and hematopoietic cell lineage ([Table 1](#table-1){ref-type="table"}).

![GO-BP function annotation the DEGs.\
The up-regulated DEGs were enriched in 62 BP, terms, and down-regulated DEGs were enriched in 34 BP terms with a cut-off criterion of count ≥2 and *P* value \<0.1. The gradual color change from green to magenta represents the −log10(P Value) change from low to high, the size of point represents the the count of genes. (A) The top five significantly enriched GO-BP terms for up-regulated DEGs. (B) The top five significantly enriched GO-BP terms for down-regulated DEGs. DEG: differentially expressed genes; GO, gene ontology; BP, biological process.](peerj-07-7628-g002){#fig-2}

![GO-CC function annotation the DEGs.\
The up-regulated DEGs were enriched in 21 CC terms, and down-regulated DEGs were enriched in 22 CC terms with a cut-off criterion of count ≥2 and *P* value \<0.1. The gradual color change from green to magenta represents the −log10(P Value) change from low to high, the size of point represents the the count of genes. (A) The top five significantly enriched GO-CC terms for up-regulated DEGs. (B) The top five significantly enriched GO-CC terms for down-regulated DEGs. DEG, differentially expressed genes; GO, gene ontology; CC, cellular component.](peerj-07-7628-g003){#fig-3}

![GO-MF function annotation the DEGs.\
The up-regulated DEGs were enriched in 22 MF terms, and down-regulated DEGs were enriched in 17 MF terms with a cut-off criterion of count ≥2 and *P* value \<0.1. The gradual color change from green to magenta represents the −log10(PValue) change from low to high, the size of point represents the the count of genes. (A) The top five significantly enriched GO-MF terms for up-regulated DEGs. (B) The top five significantly enriched GO-MF terms for down-regulated DEGs. DEG, differentially expressed genes; GO, gene ontology; MF, molecular function.](peerj-07-7628-g004){#fig-4}
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###### KEGG pathways of DEGs.

![](peerj-07-7628-g008)

  Term                                      Genes                                                                     Type of DEGs     *P* value
  ----------------------------------------- ------------------------------------------------------------------------- ---------------- -----------
  Transcriptional misregulation in cancer   *MEF2C, PROM1, CEBPA, LMO2, FLT3, RUNX1, HMGA2, RUNX2, MEIS1, MYC, WT1*   up-regulated     0.000
  Acute myeloid leukemia                    *CEBPA, FLT3, RUNX1, MYC*                                                 up-regulated     0.042
  Oxytocin signaling pathway                *MEF2C, CAMK2D, GUCY1A3, PPP3CA, NFATC3, CACNA2D4*                        up-regulated     0.056
  Proteoglycans in cancer                   *CD44, RRAS2, CAMK2D, HBEGF, PTCH1, MYC, SDC2*                            up-regulated     0.058
  Renin secretion                           *PTGER2, PTGER4, GUCY1A3, PPP3CA*                                         up-regulated     0.058
  MAPK signaling pathway                    *MEF2C, MAP3K5, RRAS2, GNA12, PPP3CA, NFATC3, MYC, CACNA2D4*              up-regulated     0.059
  Pathways in cancer                        *CEBPA, PTGER2, PTGER4, FLT3, GNA12, SMAD3, PTCH1, CDK6, RUNX1, MYC*      up-regulated     0.092
  MicroRNAs in cancer                       *SPRY2, CD44, VIM, ZEB2, CDK6, HMGA2, MYC, DDIT4*                         up-regulated     0.099
  Alzheimer's disease                       *APP, TNF, MME, ITPR3*                                                    down-regulated   0.053
  TGF-beta signaling pathway                *TNF, ID3, SMAD1*                                                         down-regulated   0.068
  Hematopoietic cell lineage                *TNF, MS4A1, MME*                                                         down-regulated   0.072

**Notes.**

KEGGKyoto Encyclopedia of Genes and GenomesDEGdifferentially expressed genes

PPI network construction and analysis
-------------------------------------

The STRING online database and Cytoscape were used to detected interactions between DEGs-encoded proteins by constructing PPI network. The PPI network of DEGs included 297 nodes and 410 edges ([Fig. 5](#fig-5){ref-type="fig"}). Five bio-functional modules were screened out, based on the cut-off criteria, and the maximal MCODE score of module, which consisted of 15 nodes and 75 edges, was 10.714. This module contained 11 up-regulated (e.g., *MYC*, *CD44*, and *PTPRC*, etc.) and four down-regulated (e.g., *TNF*, *MME*, and *RAG1*, etc.) DEGs ([Fig. 6](#fig-6){ref-type="fig"}). The top 10 hub genes identified by Cytoscape, using maximal clique centrality, degree and betweenness, are listed in [Table 2](#table-2){ref-type="table"}. *MYC*, *ALB*, *CD44*, *PTPRC* and *TNF* were identified as hub genes based on all three methods.

![PPI network of DEGs.\
The PPI network of DEGs included 297 nodes and 410 edges with minimum required interaction score \>0.4 (median confidence). The size of edges change from small to large represents the combined score of nodes change from low to high, the size of nodes represents the count. Red nodes represent up-regulated genes, yellow nodes represent down-regulated genes. PPI, protein--protein interaction; DEG, differentially expressed genes.](peerj-07-7628-g005){#fig-5}

![Bio-functional module of DEGs.\
The bio-functional module with the maximal MCODE score contained 11 up-regulated and four down-regulated DEGs. The size of edges change from small to large represents the combined score of nodes change from low to high, the size of nodes represents the count. Red nodes represent up-regulated genes, yellow nodes represent down-regulated genes. DEG, differentially expressed genes; MCODE, Molecular COmplex Detection.](peerj-07-7628-g006){#fig-6}

Drug-gene interactions analyses
-------------------------------

To explore potentially drugs for patients with *MLL*-R, the network of drug-gene interactions were constructed by DGIdb with 29, 783 drug-gene interactions consist of 41,100 genes and 9,495 drugs. As a result, 23 drug-gene interactions including 4 up-regulated hub genes (*MYC*, *ALB*, *CD44*, *PTPRC*) and 24 drugs were identified, as shown in [Fig. 7](#fig-7){ref-type="fig"}.

![Drug-gene interactions.\
Drug-gene interactions. Twenty-three drug-gene interactions including 4 up-regulated hub genes and 24 drugs were identified by DGIdb. Red nodes represent up-regulated hub genes and green nodes represent the drugs. DGIdb: Drug-Gene Interaction database.](peerj-07-7628-g007){#fig-7}
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###### Top 10 hub genes that evaluated by the methods including MCC (Maximal Clique Centrality), Degree and Betweenness.

![](peerj-07-7628-g009)

  Gene      MCC score   Gene      Degree score   Gene       Betweenness score
  --------- ----------- --------- -------------- ---------- -------------------
  *MYC*     22,218      *MYC*     43             *ALB*      8,542.027612
  *CD44*    22,075      *ALB*     42             *MYC*      8,398.777703
  *ALB*     21,713      *TNF*     33             *TNF*      4,702.068242
  *PTPRC*   21,310      *CD44*    26             *CD44*     4,164.511092
  *TNF*     19,364      *PTPRC*   22             *PPP3CA*   2,262.216619
  *VIM*     16,980      *VIM*     20             *SDC2*     2,006
  *WDFY2*   11,570      *SMAD3*   18             *FLT3*     1,790.958256
  *MME*     10,849      *FLT3*    17             *MAP3K5*   1,762.347815
  *ANXA5*   8,334       *ANXA5*   15             *SMAD3*    1,738.446661
  *FUT4*    7,200       *MME*     14             *PTPRC*    1,709.765874

Discussion
==========

MLL, encoded by the histone-lysine N-methyltransferase 2A (*KMT2A*), is a transcriptional coactivator that binds with other proteins in complex and methylates histone H3 lysine 4 which acts as an instructive mark for transcription initiation ([@ref-37]). Rearrangements of *MLL* results in the fusion of its N-terminus with the C-terminus of a partner gene, leading to transcription dysregulation ([@ref-1]). Previous research identified more than 90 fusion genes of *MLL*, including the frequent *MLL* rearrangement in infant ALL t(4;11)(q21;q23), which results in the *MLL-AF4* fusion ([@ref-35]; [@ref-36]). In the present study, three partner genes accounted for 92.8% of 139 cases: *MLL-AF4* (55.4%), *MLL-ENL* (27.3%), and *MLL-AF9* (10.1%). To confirm that the molecular mechanisms responsible for *MLL*-R infant ALL differs from those of childhood or non-*MLL*-R, we analyzed differences in gene expression profiles between *MLL*-R and non-*MLL*-R infant ALL samples, based on microarray datasets obtained from the GEO database. Two microarray datasets were selected, and a total of 320 DEGs with fold-change \>2 were screened out, including 236 up-regulated genes (e.g., *LAMP5*, *PROM1*, *CCNA1*, *MEIS1*, and *KCNK12*) and 84 down-regulated genes (e.g., *PLEKHG4B*, *NRN1*, *ELK3*, *CMTM8*, and *MME*). These results provide preliminary evidence for the distinct mechanisms of *MLL*-R infant ALL. We further investigated the functions of these DEGs and their possible roles in *MLL*-R infant ALL using DAVID functional annotations. In GO-BP, the top three significant terms were homophilic cell adhesion, negative regulation of apoptosis and cellular responses to drugs. Homophilic cell adhesion, mediated by the up-regulation of protocadherin (*PCDH*) *γ* subfamily of genes (e.g., *PCDHGA*, *PCDHGB*, *PCDHGC*) may contribute to cell migration and invasion. Previous studies have confirmed that *PCDH* genes were involved in tumorigenesis and metastasis of gastric cancer, follicular lymphoma and non-small cell lung cancer ([@ref-39]; [@ref-62]; [@ref-63]), although other studies have found that *PCDH* genes were implicated in tumor suppression ([@ref-12]; [@ref-58]). However, the role of *PCDH* genes in *MLL*-R ALL is currently unclear. SOCS2, one of the up-regulated DEGs enriched in negative regulation of apoptosis, is demonstrated to be a feedback inhibitor of JAK-STAT signaling pathways. High levels of SOCS2 was identified as an adverse prognostic characteristic of acute myeloid leukemia (AML) and ALL, such as those with *MLL* rearrangement or *BCR/ABL* fusions ([@ref-22]; [@ref-55]). *MEF2C*, *RAP2A*, *PDE4A*, *PPP3CA*, *PRNP*, and *MYC* were enriched in the GO-BP term cellular responses to drugs which may be involved in chemoresistance. As a transcription factor related to normal hematopoiesis, myocyte enhancer factor 2C (MEF2C) was involved in a number of transcriptional complexes ([@ref-10]). *MEF2C* was significantly up-regulated in acute leukemia with *MLL*-R, while known as an adverse prognostic marker in AML ([@ref-32]). Recent research suggested that *MEF2C* was related to AML chemoresistance caused by the phosphorylation of MEF2C S222 ([@ref-8]). *PDE4A*, encodes one of phosphodiesterases (PDEs), is abundantly expressed in leukemia cell lines. Inhibitors of *PDE4* augmented apoptosis induced by glucocorticoid and overcame the resistance to glucocorticoid in leukemia cells ([@ref-15]; [@ref-41]).

We further uncovered molecular mechanistic insights of *MLL*-R ALL by KEGG pathway analysis, using the DAVID tool. The most significant pathway affected was transcriptional misregulation in cancer, which was enriched with up-regulated DEGs, including *MEF2C*, *PROM1*, *CEBPA*, *LMO2*, *FLT3*, *RUNX1*, *HMGA2*, *RUNX2*, *MEIS1*, *MYC*, and *WT1*. Some of these genes have been defined as *MLL* targets genes. MEIS1, which is known as a key regulator in transcriptional regulation, cellular differentiation, and cell-cycle control, exhibited significant increases in both MLL fusion protein binding and mRNA expression on *MLL-ENL* activation in *MLL-ENL* leukemia cases and in an inducible cellular model ([@ref-57]). Further research also indicated that MEIS1 was essential for the development of *MLL* leukemia, by promoting cell differentiation resistance, and it was also confirmed to be involved in chemotherapy resistance ([@ref-44]). As a downstream gene, *HMGA2* was positively regulated by MLL fusion proteins in infant *MLL-AF4* ALL leukemic cells ([@ref-59]). *PROM1* is a commonly used stem cell and cancer stem cell marker, and *MLL-AF4* was shown to promote *PROM1* transcription, which is required for *MLL-AF4*-driven leukemia cell growth ([@ref-34]). FLT3 is a class III receptor tyrosine kinase that plays an important role in hematopoietic stem cell development, high levels of *FLT3* are a common cooperating event in *MLL-AF4* ALL ([@ref-9]). The presence of activating *FLT3* mutations in *MLL* is in keeping with a multistep pathway of leukemogenesis, suggesting that *FLT3* mutations may act as a second hit to lead to leukemogenesis in *MLL*-R infants ([@ref-28]). *LMO2* plays an important role in hematopoiesis and leukemogenesis, Begay-Muller's research indicated that AF6, a recurrent fusion partner of *MLL*, bound to *LMO2* and may be involved in mixed lineage leukemia ([@ref-5]). *RUNX1* is known to be a putative target gene of *MLL* fusions, and was highly expressed in *MLL-AF4* ALL cases, when compared with normal bone marrow cells ([@ref-20]; [@ref-31]). The *BET* inhibitor I-BET151, arrested the growth of *MLL-AF4* infant leukemic cells *in vitro* through gene deregulation, including *RUNX1* ([@ref-3]).

We examined interrelationships among the DEGs by constructing a PPI network using the STRING database and Cytoscape, and identified *MYC*, *ALB*, *CD44*, *PTPRC* and *TNF* as hub genes. *MYC* has been shown to be a direct target of *MLL-AF9* and is differentially expressed between neonatal and adult cells expressing *MLL-AF9* ([@ref-64]). Notably, expression of the neonatal, but not the adult *MLL-AF9* signature, was also enriched in a core *MYC* network, suggesting that neonatal cells are inherently more prone to *MLL-AF9*-mediated immortalization than adult cells ([@ref-25]). Furthermore, MYC was essential for *MLL-ENL* to promote differentiation arrest of myelomonocytic precursor cells, and constitutive MYC expression cooperated with *MLL-ENL* to transform cells, with irreversible maturation arrest ([@ref-45]). *CD44* is a type I transmembrane glycoprotein and a leukocyte marker expressed on hematopoietic cells, various epithelial cell types, fibroblasts, and endothelial cells. The current findings revealed that CD44 is a surface marker of cancer stem cells ([@ref-61]). *MLL*-R ALL had a unique genetic profile clearly distinguishable from those of other types of leukemia, with very high *CD44* levels ([@ref-53]). Furthermore, *CD44* expression represented the early steps of lymphoid development, high levels of *CD44* were associated with maturation arrest at an early lymphoid progenitor stage of development, while levels decreased with maturation ([@ref-2]). *PTPRC* gene encodes for the protein tyrosine phosphatase *CD45,* which acts as a haematopoietic *JAK* phosphatase required for lymphocyte activation and development ([@ref-27]; [@ref-52]). High levels of *PTPRC* (*CD45*) were associated with poor prednisone response followed by an inferior prognosis in B-cell-precursor ALL and T-cell ALL with *MLL-AF4* ([@ref-11]). However, the roles of ALB up-regulation and *TNF* down-regulation in *MLL*-R ALL remain unclear. Besides, it should be noted that *NG2* was widely known as a marker and therapeutic target for *MLL*-R leukemia ([@ref-6]; [@ref-24]; [@ref-33]; [@ref-48]; [@ref-60]), but it was not be identified as hub gene in this study may be caused by the special threshold used for the computational analyses.

In addition, 24 antineoplastic drugs were forecasted based on up-regulated hub genes. Some of these drugs have been used in the treatment of acute leukemia ([@ref-13]; [@ref-38]; [@ref-46]; [@ref-50]). The rest of them could be potential treatment options for infant *MLL*-R ALL.

Nevertheless, it should be noted that the results of this research were obtained by bioinformatics analysis, further experimental and clinical validation should be the focus of our future research.

Conclusions
===========

In this study, bioinformatics analyses were performed to detected novel candidate biomarkers and uncover possible molecular mechanisms of *MLL*-R infant ALL. The results indicated that the hub genes *MYC*, *ALB*, *CD44*, *PTPRC* and *TNF*, together with some biological events including negative regulation of apoptotic processes, monocyte differentiation, homophilic cell adhesion, and transcriptional misregulation, may contributed to leukemogenesis, migration, and invasion in *MLL*-R infant ALL. And several drugs were predicted based on the hub genes. All these findings provide novel biomarkers and potential therapeutic approaches for *MLL*-R infant ALL.
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